Physician profile
Robert Henry Osher
NPI 1831126341
$719,661.26
in general payments reported to CMS, 2019-2025
21 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208K · 2020: $182K · 2021: $104K · 2022: $108K · 2023: $89K · 2024: $29K · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Travel and Lodging: $5,825 · Education: $3,750 · Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $73,319.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,942.93 |
| Travel and Lodging | $5,825.27 |
| Education | $3,750.00 |
| Food and Beverage | $876.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $225,232.24 | 2019-2023 | Cirrus Hd-Oct, Visumax, Iolmaster 700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $108,805.50 | 2019-2021 | |
| Beaver-Visitec International, INC. | $103,734.41 | 2019-2025 | |
| Eyepoint US, INC. | $88,307.41 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $73,494.58 | 2022-2024 | Envista Mx60 Iol, Stellaris, Vyzulta |
| Omeros Corporation | $45,000.00 | 2019-2020 | |
| Microsurgical Technology, INC. | $27,500.00 | 2022 | |
| Hoya Medical Singapore Pte LTD | $22,907.65 | 2020-2023 | Vivinex |
| Hoya Surgical Optics Gmbh | $15,942.93 | 2024 | |
| Allergan, INC. | $6,607.51 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $849.62 | 2022 | |
| Alcon Vision LLC | $606.51 | 2019-2025 | Clareon, Centurion |
| Regeneron Healthcare Solutions, INC. | $300.02 | 2019-2023 | Eylea |
| Abbvie INC. | $95.86 | 2022-2024 | |
| Rxsight INC | $75.00 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $49.91 | 2025 | Iheezo, Vevye |
| Johnson & Johnson Surgical Vision, INC. | $45.26 | 2023 | Tecnis Iol |
| Thea Pharma INC. | $39.84 | 2024-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $24.91 | 2020 | |
| Haag-Streit USA, INC. | $22.89 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $19.21 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Osher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.